Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence - Takeaways - MDSpire

Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence

  • By

  • Akif Mirioglu

  • Kaan Ali Dalkir

  • Mehmet Yigit Gokmen

  • Melih Bagir

  • Kivilcim Eren Ates

  • Mehmet Ali Deveci

  • Gülfiliz Gönlüşen

  • Hilmi Serdar Ozbarlas

  • June 12, 2026

  • 0 min

Share

  • 1

    Giant cell tumor of bone (GCTB) has a recurrence rate of 15–30% and a metastasis rate of approximately 5%.

  • 2

    HtrA1 expression may serve as a potential indicator for predicting outcomes in patients with GCTB.

  • 3

    The study included 34 patients diagnosed with GCTB, with a minimum follow-up period of 24 months for recurrence assessment.

  • 4

    HtrA1 immunostaining was evaluated using a five-tiered semi-quantitative system to assess expression levels.

  • 5

    Statistical analyses included Fisher’s exact test and Kaplan–Meier analysis to evaluate recurrence and survival.

Original Source(s)

Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence

  • by Akif Mirioglu, Kaan Ali Dalkir, Mehmet Yigit Gokmen, Melih Bagir, Kivilcim Eren Ates, Mehmet Ali Deveci, Gülfiliz Gönlüşen, Hilmi Serdar Ozbarlas

  • June 12, 2026

Related Content

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma